Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Serbia Extends Galenika Tender Again Giving Valeant More Time

April 30 (Bloomberg) -- Serbia set May 31 as the new deadline in the tender for Galenika AD, giving a unit of Canada’s Valeant Pharmaceuticals International Inc another month to make an offer for the state-owned drugmaker.

The third extension since offers were first invited on Jan. 15 comes more than two weeks after the government narrowed its choice of potential investors to Valeant Pharmaceuticals North America Llc, expecting a proposal by today, the Finance and Economy Ministry said on its website.

Serbia has sought a strategic partner for Galenika among drug makers with operating revenue of at least 200 million euros ($261 million) in 2011. Galenika, based in Zemun, near the capital Belgrade, narrowed its loss in 2012 to 5.6 billion dinars ($66.2 million) from 13.5 billion dinars a year earlier.

To contact the reporter on this story: Misha Savic in Belgrade at msavic2@bloomberg.net

To contact the editor responsible for this story: James M. Gomez at jagomez@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.